© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Impact of 
-tocopherol on cardiac hypertrophy due to energy metabolism disorder: the involvement of 1,2-diacylglycerol
aDepartment of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
bDepartment of Pathology, Nagoya University Hospital, Nagoya, Japan
kenji{at}med.nagoya-u.ac.jp
* Corresponding author. Tel.: +81-52-744-2168; fax: +81-52-744-2177.
Objective: The juvenile visceral steatosis (JVS) mouse, a murine model of systemic carnitine deficiency, shows a disorder of fatty acid oxidation and develops cardiac hypertrophy associated with lipid accumulation. Recently, 
-tocopherol was shown to decrease 1,2-diacylglycerol (DAG) levels. We investigated the involvement of DAG in cardiac hypertrophy due to energy metabolism disorder by evaluating the effects of -tocopherol administration on the hearts of JVS mice. Methods: Both JVS and control mice were fed a high -tocopherol diet or a standard diet from 4 to 8 weeks of age. Myocardial DAG levels and fatty acid composition were assessed at 8 weeks of age. Results: The ventricular to body weight ratio in the JVS mice was significantly higher than that in the control mice [11.2±0.1 (mean±S.E.M.) versus 3.8±0.1 mg/g, P<0.01], and was reduced by -tocopherol treatment (9.7±0.2 mg/g, P<0.01 versus JVS mice). However, echocardiographic analysis showed the exaggeration of left ventricular dilatation in the -tocopherol treated JVS mice (P<0.01 versus JVS mice). The myocardial thiobarbituric-acid-reactive substance level was not affected by -tocopherol treatment. The myocardial DAG level was 2.5-fold higher in the JVS mice compared with that in the control mice (2004±136 versus 806±36 ng/mg dry weight, P<0.01) with a significant increase in 18:1 and 18:2 fatty acids. -Tocopherol treatment reduced myocardial DAG levels in the JVS mice (1443±49 ng/mg dry weight, P<0.01 versus JVS mice) without any alteration of the fatty acid composition. Conclusions: -Tocopherol treatment may partially reduce cardiac hypertrophy but it may also depress cardiac function in the JVS mice by decreasing the myocardial DAG level. An increase in DAG might be involved in the development of cardiac hypertrophy and in the maintenance of cardiac function in energy metabolism disorder of the heart.
KEYWORDS Cardiomyopathy; Hypertrophy; Lipid metabolism; Second messengers; Signal transduction
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Takahashi, T. Asai, H. Murakami, R. Murakami, M. Tsuzuki, Y. Numaguchi, H. Matsui, T. Murohara, and K. Okumura Pressure Overload-Induced Cardiomyopathy in Heterozygous Carrier Mice of Carnitine Transporter Gene Mutation Hypertension, September 1, 2007; 50(3): 497 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Asai, K. Okumura, R. Takahashi, H. Matsui, Y. Numaguchi, H. Murakami, R. Murakami, and T. Murohara Combined therapy with PPAR{alpha} agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency Cardiovasc Res, June 1, 2006; 70(3): 566 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Takahashi, K. Okumura, T. Asai, T. Hirai, H. Murakami, R. Murakami, Y. Numaguchi, H. Matsui, M. Ito, and T. Murohara Dietary fish oil attenuates cardiac hypertrophy in lipotoxic cardiomyopathy due to systemic carnitine deficiency Cardiovasc Res, November 1, 2005; 68(2): 213 - 223. [Abstract] [Full Text] [PDF]
|
|